Antisense oligonucleotides: from design to therapeutic application.
about
Epigenetic associations in relation to cardiovascular prevention and therapeuticsProspects for nucleic acid-based therapeutics against hepatitis C virusAntisense oligonucleotides: treating neurodegeneration at the level of RNARecent Developments in Peptide-Based Nucleic Acid DeliveryProgress toward therapy with antisense-mediated splicing modulationUsing microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipelineManagement of hepatitis delta: Need for novel therapeutic optionsThe effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophyRNA therapeutics: RNAi and antisense mechanisms and clinical applicationsAntisense DNA parameters derived from next-nearest-neighbor analysis of experimental data.Optimization of a novel biophysical model using large scale in vivo antisense hybridization data displays improved prediction capabilities of structurally accessible RNA regionsSynthesis of lipid-oligonucleotide conjugates for RNA interference studies.In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.Synthesis of Morpholino Monomers, Chlorophosphoramidate Monomers, and Solid-Phase Synthesis of Short Morpholino Oligomers.Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotidesA review of antisense therapeutic interventions for molecular biological targets in asthma.Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosisComputational prediction of efficient splice sites for trans-splicing ribozymes.Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods.DNA methylation regulates neuronal glutamatergic synaptic scaling.ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?The hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells.Bioconjugation of oligonucleotides for treating liver fibrosis.Salt-sensitive hypertension induced by decoy of transcription factor hypoxia-inducible factor-1alpha in the renal medulla.Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Formation of S-Cl phosphorothioate adduct radicals in dsDNA S-oligomers: hole transfer to guanine vs disulfide anion radical formationAdvances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Carrier-free Gene Silencing by Amphiphilic Nucleic Acid Conjugates in Differentiated Intestinal Cells.Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Biological barriers to therapy with antisense and siRNA oligonucleotides.STAT3 inhibition of gluconeogenesis is downregulated by SirT1Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).Exploiting Long Noncoding RNAs as Pharmacological Targets to Modulate Epigenetic Diseases.Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseasesNucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression.Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.Use of RNA in drug design.
P2860
Q26771428-A8E0330F-0D1C-4BE9-88DF-E4E79B329833Q26852368-3D3E4A2D-C8EA-4D77-B8F0-7DA4655ACA64Q27007056-468C7775-F787-4436-AFA4-10A1F054DB2EQ27487857-F244DA76-3963-44D0-AD94-01AE44EED39DQ27489807-4894B848-4D65-494C-8492-78F181BAA3FAQ27694686-B114EC46-604A-417E-9F75-77EA4EC69A3CQ28082312-232A2ED8-C3A4-4712-909F-B5FD8537CE93Q28484390-1FAAD232-E2FE-4617-BE4C-1E9B50E6577BQ28829240-EC504F02-6351-432D-9014-DE84C01751ACQ33578324-FBCA6C65-3681-480B-AD54-5FAC9EB39073Q33701411-19F69516-9C99-4B26-9CE5-57648A74B4EDQ33825496-CA2C4EA4-79E2-4F5F-AE18-FD09DF010F27Q33905151-1C9996A5-BB78-4969-81DC-4692C0915F5DQ34044942-117D4889-6F8A-4FE9-AE23-2DCDA03FEDCBQ34879217-1C7AEB15-681C-4526-9CD0-8D44611B8985Q34999502-26EB403A-8E94-47B0-9E26-D7D56AB57D4BQ35723980-04E66842-6F81-41BF-87AC-38B9E3197418Q35775827-E8C29215-F92E-42D6-8E1D-EA8A8A4C957EQ36302402-B06C6655-8F4F-4328-914B-3A7CB9AB3B75Q36608491-B33C9991-98E5-4B64-B276-F2CE713D81E5Q36937561-2C1F474F-3E65-4B59-965A-8AEABC85F0ECQ36962890-B11EE6ED-1A1A-412C-ADCF-8D3F112FC024Q37043515-9492C2A5-C9E7-48D6-9727-04B15FBD81B3Q37113519-F47AEA22-F5AE-47A2-B1CA-2CFE50CFB3F7Q37189998-A3C1F818-FA1C-4E31-94BF-08E374387D17Q37193000-A7BA1C2C-A249-45D5-8D8C-61831CDBDFE1Q37212878-AB0B29A4-9D25-4E98-873C-0A7A2B4E8BB1Q37321859-614BF491-A306-40AA-AC2E-BF5A3E052C89Q37325084-F8E20FBA-D768-445D-9603-F6A90F8D9E91Q37330601-3AE584FA-EDB9-40C8-9858-FB29AF6AA72AQ37347451-C750249C-4B5D-4FEA-B60F-56DE708B9397Q37370563-7AE052E3-5A6E-4BE3-AA94-9F4F8BD4E456Q37378340-E290ED74-9944-4199-A7CB-121321F6531CQ37466250-39CD219F-8285-4C95-A48F-2E38235DB4DEQ37586844-F63185C9-E0BB-4BAB-9638-B0F26251122FQ37724407-51A93285-AA42-4FAF-9AE5-7D7E78D06FD4Q37819299-1DCE953A-A9C2-489F-A9F4-F26AC0F60850Q37981217-909D4FFB-8D1B-4C3E-A0FF-B07FBEC80F77Q38061684-B95AFC64-326E-4A9D-BCAF-041EE12416CCQ38089160-894951DD-F9C3-4DBA-B8F6-7859841C95DE
P2860
Antisense oligonucleotides: from design to therapeutic application.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antisense oligonucleotides: from design to therapeutic application.
@ast
Antisense oligonucleotides: from design to therapeutic application.
@en
type
label
Antisense oligonucleotides: from design to therapeutic application.
@ast
Antisense oligonucleotides: from design to therapeutic application.
@en
prefLabel
Antisense oligonucleotides: from design to therapeutic application.
@ast
Antisense oligonucleotides: from design to therapeutic application.
@en
P2093
P2860
P1476
Antisense oligonucleotides: from design to therapeutic application.
@en
P2093
Jasmine H P Chan
Shuhui Lim
W S Fred Wong
P2860
P304
P356
10.1111/J.1440-1681.2006.04403.X
P577
2006-05-01T00:00:00Z